By Frank Prenesti
Date: Monday 22 Sep 2025
(Sharecast News) - AstraZeneca and Amgen on Monday said their Tezspire drug has been recommended for approval in the European Union for the treatment of adult patients with chronic rhinosinusitis with nasal polyps.
| SEP cashes in as US giant Amgen buys cancer drug... | 26-Jan-2011 | The Scotsman |
| Amgen Buys a Cancer Drug Maker | 25-Jan-2011 | New York Times |
| Tech Ticker | 16-Dec-2010 | BayArea.com |
| Amgen drug delayed spread of prostate cancer to ... | 15-Dec-2010 | LA Times |
| Business Briefing | 24-Dec-2009 | LA Times |
| Currency | US Dollars |
| Share Price | $ 327.64 |
| Change Today | $ 0.33 |
| % Change | 0.10 % |
| 52 Week High | $329.19 |
| 52 Week Low | $325.01 |
| Volume | 1,539,731 |
| Shares Issued | 536.90m |
| Market Cap | $175,910m |
| RiskGrade | 100 |
| Strong Buy | 6 |
| Buy | 8 |
| Neutral | 15 |
| Sell | 2 |
| Strong Sell | 1 |
| Total | 32 |

| Time | Volume / Share Price |
| 15:59 | 80 @ $327.76 |
| 15:59 | 100 @ $327.73 |
| 15:59 | 75 @ $327.70 |
| 15:59 | 100 @ $327.78 |
| 15:59 | 45 @ $327.79 |
You are here: research